PharmAkea has developed orally available, small-molecule inhibitors of two fibrotic molecular targets: the secreted enzymes lysyl oxidase-like 2 (LOXL2) and autotaxin (ATX). Currently, the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback